1. Use of urinary biomarkers in cancer of the bladder: Current status
- Author
-
Rajendra B Nerli, Shridhar C Ghagane, Sanjay Vijay Pujar, and Shadab Sadiq Rangrez
- Subjects
bladder cancer ,exosomes ,guidelines ,liquid biopsy ,microrna ,urinary biomarkers ,Medicine - Abstract
Bladder cancer (BCa) is a common genitourinary cancer worldwide. It has been further classified into muscle invasive bladder cancer and nonmuscle invasive bladder cancer. Currently, the detection of BCa requires an unpleasant and expensive cystoscopy and biopsy, which is often accompanied by several adverse effects. Thus, a need is felt to develop novel diagnostic methods for initial detection and surveillance of the disease. Several urine-based tests have been approved by the Food and Drug Administration, USA, for the detection and surveillance of BCa, which are also commercially available. However, as of today, the sensitivity, specificity, and diagnostic accuracy of these urine-based assays are still suboptimal. To improve these, a number of novel molecular markers as well as multiple assays need to be introduced in clinical practice. At present, there is a growing need and evidence toward the use of minimally invasive “liquid biopsy” to identify biomarkers in BCa. DNA- and RNA-based markers in body fluids such as urine appear as promising potential markers in diagnostic, prognostic, predictive, and monitoring BCa. We report a nonsystematic review of the literature in regard to urinary biomarkers for BCa.
- Published
- 2019
- Full Text
- View/download PDF